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Mutations in DDR2 Gene Cause SMED
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The spondylo-meta-epiphyseal dysplasia [SMED] short limb-hand type [SMED-SL] is a rare autosomal-recessive disease, ﬁrst reported by
Borochowitz et al. in 1993.1 Since then, 14 affected patients have been reported.2–5 We diagnosed 6 patients from 5 different consan-
guineous ArabMuslim families from the Jerusalem area with SMED-SL. Additionally, we studied two patients fromAlgerian and Pakistani
ancestry and the parents of the ﬁrst Jewish patients reported.1 Using a homozygosity mapping strategy, we located a candidate region on
chromosome 1q23 spanning 2.4Mb. The position of the Discoidin Domain Receptor 2 (DDR2) gene within the candidate region and the
similarity of the ddr2 knockout mouse to the SMED patients’ phenotype prompted us to study this gene6. We identiﬁed three missense
mutations c.2254 C > T [R752C], c. 2177 T > G [I726R], c.2138C > T [T713I] and one splice site mutation [IVS17þ1g > a] in the
conserved sequence encoding the tyrosine kinase domain of the DDR2 gene. The results of this study will permit an accurate early
prenatal diagnosis and carrier screening for families at risk.The spondylo-epiphyseal-metaphyseal dysplasia [SMED]
are a group of heterogeneous disorders all deﬁned by the
combination of vertebral, epiphyseal, and metaphyseal
involvement.7 In 1993, Borochowitz et al. reported on
a new autosomal-recessive SMED with short limb-hand
type (SMED, short limb-hand type [MIM 271665]).1 Later,
Langer et al. emphasized the importance of the chondral
calciﬁcations in the diagnosis of this dysplasia and
proposed to call it SMED, short limb-abnormal calciﬁcation
type (SMED-SL).2 Here, we report on eight patients from
seven different consanguineous families with SMED-SL:
six patients fromﬁve ArabMuslim families from the Jerusa-
lem area, one Algerian patient, and one Pakistani patient.
The diagnostic clinical and radiological criteria included
disproportionate, short stature; platyspondyly; abnormal
epiphyses and metaphyses; shortening of the lower and
upper limbs; short, broad ﬁngers; and premature calciﬁca-
tions. This report brings the number of patients to 20 and
the number of consanguineous families to 13 out of the
17 families reported. The postnatal clinical features of the
six ‘‘Jerusalem’’ patients are summarized and compared to
data in the literature (Table 1). All the patients presented
with typical short hands and broad, puffy ﬁngers (Figure 1).
Follow up of the patients permitted us to conﬁrm that this
dysplasia is progressive with respect to the severity of the
bowing of the lower limbs and to the appearance of the
calciﬁcations. Indeed, three of the patients werewheelchair
bound from age 11. The chondral calciﬁcations were docu-
mented only after 8 years of age and were extremely prom-
inent in the 16-year-old patient, who showed calciﬁcations
of the larynx, trachea, and costal cartilages and the choroids80 The American Journal of Human Genetics 84, 80–84, January 9, 2plexus (Figure 2). The same patient was severely affected
with dense calciﬁcations over the left femoral head pubis
and ischium (Figure 3).
Platyspondyly of the cervical spine with widened disc
spaces was already detected at the age of 1 year and was
a major ﬁnding in all the patients. Four patients presented
with atlanto axial instability already from age 3, and three
of them required neurosurgery decompression at ages 10,
11, and 16, respectively.
The rarity of the disease, the common geographic origin,
and the consanguinity of these families prompted us to use
a homozygosity mapping strategy as a ﬁrst step for gene
identiﬁcation. Although homozygosity mapping has
been shown to be a powerful method for localizing genes
causing autosomal-recessive diseases in consanguineous
families, this strategy has potential pitfalls because disease
mutations can arise on nonhomozygous haplotypes,
although this is quite rare.8 Blood samples of the patients
and family members were obtained after informed consent
was obtained from the institutional review board (0127-
08-HMO) and the patients. DNA was extracted from
whole blood, ﬁbroblasts, or lymphoblastoid lines by stan-
dard methods. We analyzed the DNA of three unrelated
patients of the Jerusalem families by using an Affymetrix
human mapping 250K (NspI) array with an average
distance of 12 Kb between the SNPs (Figure 4). We manu-
ally detected homozygous regions by looking for shared
homozygous regions larger than 5 cM.9 Among the homo-
zygous intervals shared by the three patients studied, the
largest one was 2.4 Mb on chromosome 1q23 (it was
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rs10799915 [161622219]). This critical region contains
approximately 50 different genes, including the gene
coding for Discoidin Domain Receptor 2 (DDR2 [MIM
191311]), which was a strong candidate because of the
similarity between the phenotype of the ddr2 knock-out
mouse and that of the patients. The ddr2/ mouse gener-
ated by Labrador et al. in 2001 developed a skeletal pheno-
type characterized by shortening of long bones, irregular
growth of ﬂat bones, and a short snout.6 The reduced
chondrocyte proliferation and bone growth found in
the ddr2/ mouse was compatible with the previously
reported extremely abnormal cartilage documented at
the costochondral junction of one SMED-SL patient.1,5,6
The DDR2 gene is a member of the receptor tyrosine kinase
[RTK] family and is involved in signal transduction.10,11
The DDR2 protein consists of an extracellular discoidin
domain and a cytosolic tyrosine kinase domain (TK).10,11
This cell-surface receptor tyrosine kinase is activated by
the binding of its discoidin domain to ﬁbrillar collagen
and is mainly expressed in mesenchymal cells12,13. We
tested for mutations at the cDNA level. We extracted
RNA from ﬁbroblasts or lymphoblastoid lines (1.106 cells)
by using the high pure RNA isolation kit (Roche) according
Table 1. Summary of the Clinical Findings of the Six
Jerusalem Patients Compared to Findings in the Literature
Literature Present Report Total
Number of Patients (14 Patients) (6 Patients) (20 Patients)
Short broad hands 14 6 20
Short puffy fingers 2 6 8
Shortening of lower and
upper limbs
14 6 20
Bowing of legs 1 6 7
Pectus excavatum 5 1 6
Narrowed chest 8 6 14
Respiratory disease 8 3 11
Large open fontanel 5 3 8
Large broad face 7 6 13
Saddle, short, flat nose 11 6 17
Wide nostrils 11 6 17
Long philtrum 10 6 16
Hypertelorism telecanthus 11 6 17
Abnormal teeth 1 2 3
Short neck 1 6 7
Neck hyperextension 2 2 4
Peculiar voice 3 1 4
Hypotonia 5 6 11
Delayed motor
development
9 6 15
Delayed mental
development
4 0 4
Platyspondyly 14 6 20
Broad and short long
bones
14 6 20
Broad and short round
bones
14 6 20
C1-C2 instability 7 4 11
Chondral calcifications 3 4 7
Rib abnormalities 14 6 20
Abnormal metaphyses and
epiphyses
14 6 20The Ato the manufacturer’s instructions. The DDR2 transcript
(accession number NM_006182.2. GI:62420883) was
divided into 5 overlapping fragments (Table S1 in the
Supplemental Data available online). First-strand cDNA
was synthesized with Superscript II (Invitrogen), then
Figure 1. Clinical Picture and Roentgen of the Hands
(A and B) Picture of the hands of 2 patients with typical broad,
puffy fingers and short, broad nails.
(C) Hand radiography of patient A shows irregular widened distal
radius and ulna. The metacarpals are short and have a narrow
neck with meta-epiphyseal widening and distal pointing.
Figure 2. Roentgen of the Cervical Spine, Chest, and Comput-
erized Tomography of the Head and Chest of a 16-Year-Old
Patient
Lateral cervical radiography (A) and chest CT (B) showing heavily
calcified larynx and tracheal rings (white arrows). (C) Brain CT of
the 16-year-old patient demonstrates choroid plexus calcifications
not seen normally at this age (white arrow). (D) Chest radiography
demonstrates widened ribs and a heavily calcified distal bronchial
tree (white arrow).merican Journal of Human Genetics 84, 80–84, January 9, 2009 81
ampliﬁed, puriﬁed (QIA quick gel extraction kit) and
sequenced with the BigDye terminator system on an ABI
prism 3700 sequencer. Sequence analysis of the patients’
cDNA permitted us to identify three missense mutations,
all localized in exon 17 of the DDR2 gene. The mutation
c.2254 C > T [R752C] was found in the six patients from
the Jerusalem families; the mutations c. 2177 T > G
[I726R] and c.2138C > T [T713I] were identiﬁed in the Al-
gerian and in the Pakistani patients, respectively. Study of
the consanguineous parents of the Jewish patients revealed
abnormal short transcripts. At the genomic level, both
parents were carriers of a splice mutation IVS17þ1g > a.
To test and screen for the different mutations, we used
the following methods. The mutation c.2254 C > T
[R752C] abolishes a restriction site for MspA1I. To identify
the c. 2177 T>G [I726R]mutation, we created a restriction
site for SacI in the mutated sequence. For mutations
c.2138C > T [T713I] and IVS17þ1g > a, we created restric-
tion sites for Tsp45I and BstNI, respectively, in the normal
sequence. In all the cases studied, parents were heterozy-
gous for the respective mutations, and the eight affected
patients were homozygous. In order to rule out a rare poly-
morphic variant, we tested a panel of 200 chromosomes of
matched healthy, unrelated individuals for each of the
three missense mutations, and no carriers were found.
We performed haplotype analysis of the family members
carrying the mutation c.2254 C > T [R752C] by selecting82 The American Journal of Human Genetics 84, 80–84, January 9, 2microsatellite markers spanning the DDR2 region
[D1S2675- D1S2768–D1S2844] from the UCSC database.
PCR products were analyzed on the ABI 3100 with
Figure 3. Antero-Posterior Radiography of the Pelvis, Femurs,
and Knees of the 16-Year-Old Patient
Dense calcifications are projected over the left femoral head pubis
and ischium (two arrows). The right acetabulum is flattened and
irregular and shows a varus deformity of the femoral neck. The
femurs and tibia metaphyses are widened.Figure 4. Partial Pedigrees of the Five Arab Muslim Jerusalem Families and Haplotype Analysis Using Three Microsatellite
Markers, D1S2675, D1S2768, and D1S2844, in the Critical Region on Chromosome 1q23, Showing a Common Haplotype
The microsatellite markers are shown in the upper left panel. An asterisk indicates the three patients studied by SNP analysis.009
Figure 5. RT-PCR of the DDR2 c.DNA and Partial Alignment of the Human DDR2 Tyrosine Kinase Domain with Sequences from Four
Different Species
(A) RT-PCR of the DDR2 c.DNA (fragment E). Panel 1: Heterozygous parent for IVS17þ1g > a (Lymphoblastoid line). Panels 2 and 3:
Normal control (lymphoblastoid line and fibroblasts, respectively). Sequencing of band c showed skipping of exon 17, band b showed
partial skipping of exon 17, and band a represents the normal allele.
(B) Partial alignment of the human DDR2 tyrosine kinase domain with sequences from four different species. The mutated residues T713C,
I726R, and R752C, highlighted and indicated by arrows, are found in SMED patients and are localized in the active site of the DDR2
tyrosine kinase domain.Genescan software. The chromosomes carrying the R752C
mutation share a commonhaplotype, suggesting a founder
mutation (Figure 4).
Analysis of the parents’ cDNA carrying the IVS17þ1g >
a revealed three different transcripts, which were
sequenced (Figure 5A). The shortest transcript c is the
result of out of frame skipping of exon 17 and includes
a premature termination codon 196 bp downstream. Tran-
script b represents partial out-of-frame skipping of exon 17
(128 bp) as a result of an alternative donor site recognized
by the spliceosome at c.2156 (GTAAGA), and transcript
a corresponds to the normal allele. Importantly, the skip-
ped exon is the same exon 17 that contains the three
missense mutations identiﬁed here.
During recent years, the DDR2 gene has been exten-
sively studied.10,11The crucial event in DDR2 cellular
signaling after ligand binding is the phosphorylation of
the tyrosines in the activation loop of the intracellular
Tyrosine Kinase [TK] domain.14 Phosphorylation of the
tyrosine residues in the activation loop causes change in
the three-dimensional structure of the activation loop
and stimulates tyrosine kinase activity by providing ATP
and peptide substrate access to the active-site pocket.15,16
DDR2 has a similar pattern of activation as well as
sequence homology to other RTKs15 and is especially
homologous to the tyrosine kinase domain of the insulin
receptor (IR [MIM 14760]). This homology enables us to
speculate on the effect of the DDR2 mutations reportedThe Ahere.14 Phosphorylation of the three tyrosine residues
[Tyr 1158, 1161, and 1162] within the activation loop of
the Insulin Receptor Tyrosine Kinase [IRTK] were shown
to be essential for IRTK autophosphorylation and tyrosine
kinase activity.16,17 These residues correspond to Tyr 736,
Tyr 740, and Tyr 741 of the DDR2 protein.14 Notably, the
three missense mutations reported here are localized in
the active site of DDR2 in the vicinity of the activation
loop near these tyrosine residues. By analogy with IRTK’s
three-dimensional conformation, threonine 713 of the
DDR2 protein should be localized in the vicinity of the
active aspartate 710 (corresponding to aspartate 1132 in
the IRTK protein). Indeed, crystallographic studies of
IRTK demonstrate that aspartate 1132 and Tyr 1162 [corre-
sponding to Tyr 740 of DDR2] form a speciﬁc hydrogen
bond within the active site of IRTK to stabilize the activa-
tion loop into an inhibitory conformation.16 We suggest
that the T713I mutation inhibits the opening of the activa-
tion loop and thus leads to abnormal switching on or
switching off of DDR2. DDR2-Ile 726 corresponds to the
IRTK gene’s Ile 1148, which localizes near D1150, which
is involved in the ATP binding. This suggests that the
mutation I726R might affect the ATP binding afﬁnity of
DDR2. The IRTK arginine 1174, which belongs to one of
the IRTK substrate binding pockets16, corresponds to
DDR2 arginine 752; We propose that the R752C mutation
affects the substrate speciﬁcity of DDR2 and thus inﬂu-
ences the downstream signaling pathways.14merican Journal of Human Genetics 84, 80–84, January 9, 2009 83
All the missense mutations identiﬁed in this work local-
ized in the active site of the DDR2 tyrosine kinase domain,
which is highly conserved among different species (Fig-
ure 5B), whereas the splice mutation causes deletion and
frameshift in this same conserved sequence.
In summary, we report for the ﬁrst time on four different
mutations in the DDR2 gene in the patients affected
with the rare autosomal-recessive spondylo-meta-epiphy-
seal dysplasia, short limb-abnormal calciﬁcation type
syndrome [SMED-SL]. Future studies will permit elucida-
tion of the downstream events mediated by DDR2. Fami-
lies at risk can now beneﬁt from carrier identiﬁcation
and early prenatal diagnosis, including preimplantation
diagnosis.
Supplemental Data
Supplemental Data include a table of primers used for the ampliﬁ-
cation of ﬁve fragments (A–E) of the DDR2 c.DNA and are available
with this article online at http://www.ajhg.org/.
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